ABOUT US​

LifeMax is a privately held, clinical stage biotech company focused on developing first-in-class or best-in-class therapeutics for orphan diseases that have few or no options. We have three clinical stage programs, LM-030, AMB-051 and AMB-053, with the lead program, LM-030, ready to enter into a pivotal trial.

May 5, 2020
LifeMax Appoints Michael Huang, MD, as Chief Medical Officer

Redwood City, California – (Business Wire) – May 05, 2020 – LifeMax Laboratories, Inc. (“LifeMax”), a private company focused on developing first-in-class or best-in-class ...

April 14, 2020
LifeMax Receives Fast Track Designation For LM-030 for the Treatment ...

Redwood City, California – (Business Wire) – April 14, 2020 – LifeMax Laboratories, Inc. (“LifeMax”), a private company focused on developing first-in-class or best-in-class...

March 30, 2020 
LifeMax Launches AmMax Bio Following The License Of Worldwide Rights...

Redwood City, California – (Business Wire) – March 30, 2020 – LifeMax Laboratories, Inc. (“LifeMax”), a private company focused on treating orphan diseases that have few or no ...

NEWS

R&D

Through in-licensing from either big pharma/biotech companies or academic institutions, we have established a robust and science-driven portfolio that targets the underlying causes of the various orphan diseases with few or no approved therapeutic options. Our focus is on first-in-class or best-in-class therapeutics that will truly bring meaningful and/or life-saving benefits to patients. We are also leveraging sponsored collaboration and research with universities to help de-risk potential projects before their adoption into our pipeline

Treating Orphan Diseases With Few or No Options.

map.png

Redwood City, CA, USA

map.png

Taipei, Taiwan

©2020 BY LIFEMAX HEALTHCARE INTERNATIONAL